Cabometyx Tablet
Product Images NDC 42388-023

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Cabometyx (NDC 42388-023). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Exelixis, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of Bottle Label (20 mg)

Cabometyx 20 mg tablets label contains cabozantinib as the active ingredient. The label specifies a 30-tablet prescription package manufactured by Exelixis, Inc., bearing the NDC 42388-024-26. It includes storage instructions, dosing recommendations to take on an empty stomach, and barcode and product identification information.*

FDA Label Image

Image Of Bottle Label (20 mg)

Cabometyx 20 mg tablets label showing oral tablets containing cabozantinib, supplied by Exelixis, Inc. The label states the package contains 30 tablets and includes directions to take one tablet daily on an empty stomach. Storage instructions specify 20°C to 25°C with allowable excursions. The label includes NDC 42388-024-26 and barcode.*

FDA Label Image

Image Of Bottle Label (professional sample)

CABOMETYX 20 mg oral tablets label, proprietary name Cabometyx with generic cabozantinib, manufactured by Exelixis, Inc. The label states 15 tablets per package for prescription use only. It includes dosage instructions to take once daily on an empty stomach and storage temperature recommendations. The label contains product identifying information including NDC 42398-024-37 and a barcode.*

FDA Label Image

Image Of Bottle Label (40 mg)

Cabometyx 40 mg tablets label with cabozantinib as the active ingredient. The label indicates oral tablets with a quantity of 30 per package, manufactured by Exelixis, Inc. Instructions warn to take once daily on an empty stomach, advise against crushing, and provide storage temperature guidelines.*

FDA Label Image

Image Of Bottle Label (40 mg)

Label for CABOMETYX (cabozantinib) tablets, 40 mg strength, oral dosage form, prescription only. The label indicates a package of 30 tablets by Exelixis, Inc. Instructions note that each tablet contains 40 mg of cabozantinib and should be taken once daily on an empty stomach. Storage conditions and usage advisories are also included.*

FDA Label Image

Image Of Bottle Label (professional sample)

CABOMETYX (cabozantinib) 40 mg tablets packaging label. The label states 'Professional Sample - Not for Sale' and indicates the product contains 15 tablets. It includes storage instructions and warns to take the tablet once daily on an empty stomach. The labeler is Exelixis, Inc. A barcode, NDC 42388-025-37, lot number, and expiration date are also visible.*

FDA Label Image

Image Of Bottle Label (60 mg)

Label for CABOMETYX (cabozantinib) tablets, 60 mg strength, oral dosage form. The label shows a 30-tablet quantity and indicates that the product is prescription-only. Manufactured for Exelixis, Inc., with storage instructions at 20°C to 25°C. The label also includes dosing advice and a barcode, along with NDC 42388-023-26.*

FDA Label Image

Image Of Bottle Label (60 mg)

CABOMETYX 60 mg tablets label showing oral tablet form containing 60 mg cabozantinib. The label includes dosing instructions to take once daily on an empty stomach, storage temperature guidelines (20-25°C with permitted excursions), and a caution to keep out of reach of children. The package contains 30 tablets and is manufactured by Exelixis, Inc. in Alameda, California.*

FDA Label Image

Image Of Bottle Label (professional sample)

Label for CABOMETYX 60 mg tablets (cabozantinib) by Exelixis, Inc. The label includes dosing instructions to take once daily on an empty stomach, storage conditions, and a barcode. It indicates a package of 15 tablets, prescription use only, and is marked professional sample - not for sale.*

FDA Label Image

Image Of Chemical Structure Of Cabometyx (Cabometyx Chem Struct)

Chemical structure of cabozantinib, the active ingredient in CABOMETYX tablets. The diagram shows the molecular framework including aromatic rings, functional groups, and atoms characteristic to cabozantinib.*

FDA Label Image

Image Of Kaplan-meier Curves Of Progression-free Survival In Meteor (first 375 Randomized) (Cabometyx Fig1)

A Kaplan-Meier chart comparing progression-free survival probabilities over 18 months for CABOMETYX (cabozantinib) tablets versus Everolimus. The Y-axis shows probability of progression-free survival from 0 to 1, and the X-axis shows time in months. The number of patients at risk is tabulated below the graph for both treatment groups at various time points.*

FDA Label Image

Image Of Kaplan-meier Curve Of Overall Survival In Meteor (itt) (Cabometyx Fig2)

A Kaplan-Meier curve chart comparing the probability of overall survival over 30 months for CABOMETYX (cabozantinib) tablets versus Everolimus. The x-axis represents time in months, and the y-axis shows the probability of overall survival ranging from 0 to 1. The chart includes a risk table below indicating the number of patients at risk for each treatment group at various time points.*

FDA Label Image

Image Of Kaplan-meier Curve Of Progression-free Survival In Cabosun (Cabometyx Fig3)

A survival probability curve chart comparing progression-free survival between CABOMETYX (cabozantinib) and Sunitinib over months. The y-axis represents the probability of progression-free survival, while the x-axis shows time in months up to 30. A table below the graph details the number of patients at risk over time for each treatment group.*

FDA Label Image

Image Of Kaplan-meier Curve Of Overall Survival In Cabosun (Cabometyx Fig4)

A Kaplan-Meier survival plot comparing the probability of survival over time in months between CABOMETYX and Sunitinib. The graph shows survival probabilities on the vertical axis and months on the horizontal axis, with patient risk counts listed below at various time points for both drugs.*

FDA Label Image

Image Of Kaplan-meier Curve Of Progression-free Survival In Checkmate-9er (Cabometyx Fig5)

A Kaplan-Meier survival curve graph showing the probability of progression-free survival per BICR (Blinded Independent Central Review) over 27 months. The graph compares two treatments: CABOMETYX + nivolumab and sunitinib. The y-axis represents the probability of progression-free survival, and the x-axis represents time in months. The number of subjects at risk is provided below the graph for both treatment groups at multiple time points.*

FDA Label Image

Image Of Kaplan-meier Curve Of Overall Survival In Checkmate-9er (Cabometyx Fig6)

A Kaplan-Meier survival curve comparing overall survival probability over 45 months for CABOMETYX plus nivolumab versus sunitinib. The x-axis represents overall survival in months, and the y-axis shows probability of overall survival. The graph includes the number of subjects at risk at different time points for both treatment groups.*

FDA Label Image

Image Of Kaplan-meier Curve Of Overall Survival In Celestial (Cabometyx Fig7)

A Kaplan-Meier survival curve chart comparing probability of survival over time in months between patients treated with CABOMETYX and placebo. The chart shows two lines, one for CABOMETYX and one for placebo, with labeled time points and numbers at risk listed below for each group at intervals from 0 to 42 months.*

FDA Label Image

Image Of Kaplan-meier Curve Of Progression-free Survival In Celestial (Cabometyx Fig8)

A Kaplan-Meier survival curve showing the probability of progression-free survival over a 36-month period comparing CABOMETYX (cabozantinib) and placebo. The graph includes number at risk data for both groups at various time points, illustrating higher survival probability for CABOMETYX compared to placebo.*

FDA Label Image

Cabometyx Fig9

A Kaplan-Meier survival curve chart showing the probability of progression-free survival over months for CABOMETYX tablets versus placebo. The graph plots probability on the vertical axis against time in months on the horizontal axis, with separate curves for CABOMETYX and placebo and a number-at-risk table below.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.